York, UK (January 31, 2023) – Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies. The ability to precisely target gene therapies, like siRNA-based therapeutics, to specific cells and tissues using Optimers offers exciting new opportunities for the field of gene therapy.
News
Become a mentor for a rare disease patient group leader who needs YOU and your skills!
This is your chance to give something back to a community that has given so much to those living with a rare disease.
Arecor Therapeutics plc
(“Arecor”, the “Company” or the “Group”)
ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE
- Ultra-concentrated, ultra-rapid acting insulin AT278, a promising candidate in the pursuit of next generation insulins to simplify and improve glycemic control
ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has taken the lease on laboratory and office facilities at MediCity Nottingham as it embarks on the next stage of its strategy to launch a translational Contract Research Organisation (tCRO).
Based in Beeston, MediCity is a medtech incubator and part of Pioneer Group, and provides resident businesses with access to a connected local and national biotech community, a strong pool of quality talent from nearby universities, and flexible laboratory space.
Cambridge UK: December 2022
PCML Group continues partnership with One Nucleus to develop engagement with One Nucleus and its members. The One Nucleus Partner Programme is tailor-made to meet the needs of the Partner and One Nucleus members.
Following a forecast 0.3% decline in GDP in Q3, the UK economy is expected to contract around 0.2% each quarter from Q4 this year through to Q2 2023, resulting in GDP falling 0.3% in 2023 as a whole. This is a significant revision from the 1% growth forecast for 2023 in the EY ITEM Club’s July Summer Forecast – although the scale of the upcoming downturn is expected to be shallow relative to previous recessions thanks, in part, to the Government’s intervention on household and business energy bills.
The US and European medical technology (MedTech) industry has performed impressively throughout the COVID-19 pandemic, but it now faces a host of new and emerging challenges as the direct impact of the global pandemic slowly subsides.
We are excited to announce that as part of our investment programme we have introduced a high-end, ultra-fast and super-efficient slide digitalization system into our workflow. The PANNORAMIC® 1000 RX, is the flagship member of the 3DHISTECH PANNORAMIC® scanner family. It is known for its unprecedented capacity, superior image quality and flexibility. A range of scanning options are available, with brightfield scanning at resolutions of 20x, 40x, with Z stack and extended focus scanning options available too.
The EY Global IPO Trends 2022 is now available showing that after a record-breaking 2021, the global IPO market took a sharp turn in the opposite direction in 2022. With only 1,333 IPOs raising US$179.5b, IPO activity dipped 45% and 61% by number of deals and proceeds, respectively, year-over-year (YOY). As the average deal size shrank due to lowered valuation and poor stock market performance, we didn’t see as many large IPOs launch in 2022.
Click here to view the full articles - https://www.ey.com/en_gl/ipo/trends